McKinsey Wins Dismissal of Most Endo Trustee Opioid Sales Claims

Sept. 30, 2025, 4:59 PM UTC

McKinsey & Co. won dismissal of most claims brought by a bankruptcy trustee who’s been pushing the consulting giant to pay for alleged harm it caused pharmaceutical maker Endo International Plc through its advice on marketing and selling opioids.

Eight of nine claims accusing McKinsey and its affiliates of helping destroy billions of dollars of Endo’s value were tossed. But the trustee can pursue recovery of $584 million in defense and professional fee costs unrelated to settlements, Judge David S. Jones of the US Bankruptcy Court for the Southern District of New York said in a 110-page decision issued Monday. ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.